Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Abstract In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non‐small cell lung carcinoma harboring mesenchymal‐epithelial transition (MET) exon 14 skipping alterations. Herein, we present a ca...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2021-12-01
Serie:	Thoracic Cancer
Ämnen:	capmatinib MET ex.14 skipping peripheral edema tepotinib
Länkar:	https://doi.org/10.1111/1759-7714.14205
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!